Hengrui Pharma Wins New China Approval for Hetrombopag Aplastic Anemia Use

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an update.

Jiangsu Hengrui Pharmaceuticals has obtained approval from China’s National Medical Products Administration to add a new indication for its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. The therapy, a prescription oral tablet, is now approved in combination with immunosuppressive therapy for treatment-naive severe aplastic anemia patients aged 15 and older, expanding the drug’s clinical use beyond its original indications.

The new indication approval enhances Hengrui’s hematology portfolio and underscores its capability in developing innovative treatments for serious blood disorders. This regulatory milestone may strengthen the company’s competitive position in China’s high-value innovative drug market and could support future revenue growth as the expanded patient population gains access to the therapy.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company focused on the research, development and commercialization of innovative drugs. The company develops prescription medicines targeting serious diseases and operates in both domestic and overseas capital markets, with shares listed in Shanghai and Hong Kong.

Average Trading Volume: 2,711,700

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$416B

See more data about 1276 stock on TipRanks’ Stock Analysis page.